Masimo Co. (NASDAQ:MASI) Director Craig B. Reynolds Sells 40,000 Shares

Masimo Co. (NASDAQ:MASI) Director Craig B. Reynolds sold 40,000 shares of Masimo stock in a transaction dated Friday, April 26th. The shares were sold at an average price of $136.17, for a total transaction of $5,446,800.00. Following the sale, the director now owns 7,406 shares of the company’s stock, valued at $1,008,475.02. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Masimo Stock Down 1.3 %

Masimo stock traded down $1.79 during trading on Tuesday, reaching $134.41. The stock had a trading volume of 408,887 shares, compared to its average volume of 553,409. Masimo Co. has a 52-week low of $75.22 and a 52-week high of $190.82. The business has a 50 day moving average price of $135.86 and a 200 day moving average price of $117.58. The company has a quick ratio of 1.22, a current ratio of 2.18 and a debt-to-equity ratio of 0.64. The stock has a market cap of $7.11 billion, a PE ratio of 89.01 and a beta of 0.97.

Masimo (NASDAQ:MASI) last issued its quarterly earnings data on Tuesday, February 27th. The medical equipment provider reported $1.25 earnings per share for the quarter, topping the consensus estimate of $0.82 by $0.43. The business had revenue of $548.90 million during the quarter, compared to the consensus estimate of $545.69 million. Masimo had a net margin of 3.98% and a return on equity of 13.77%. The company’s revenue was down 11.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.32 EPS. On average, analysts predict that Masimo Co. will post 3.51 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the stock. Piper Sandler lifted their price target on shares of Masimo from $70.00 to $117.00 and gave the company a “neutral” rating in a research report on Monday, February 26th. Stifel Nicolaus upgraded shares of Masimo from a “hold” rating to a “buy” rating and lifted their price objective for the company from $148.00 to $170.00 in a report on Monday, April 15th. StockNews.com upgraded shares of Masimo from a “sell” rating to a “hold” rating in a report on Friday, March 29th. BTIG Research lifted their price objective on shares of Masimo from $145.00 to $166.00 and gave the company a “buy” rating in a report on Monday, March 25th. Finally, Wells Fargo & Company upgraded shares of Masimo from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $117.00 to $160.00 in a report on Monday, March 25th. Five research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, Masimo presently has a consensus rating of “Hold” and a consensus target price of $137.43.

Hedge Funds Weigh In On Masimo

A number of institutional investors have recently modified their holdings of MASI. Riverview Trust Co acquired a new position in shares of Masimo in the 1st quarter valued at $25,000. Massmutual Trust Co. FSB ADV increased its holdings in shares of Masimo by 140.6% in the 4th quarter. Massmutual Trust Co. FSB ADV now owns 243 shares of the medical equipment provider’s stock valued at $28,000 after acquiring an additional 142 shares during the period. Byrne Asset Management LLC acquired a new position in Masimo in the 4th quarter valued at $28,000. NBC Securities Inc. acquired a new position in Masimo in the 3rd quarter valued at $34,000. Finally, EverSource Wealth Advisors LLC increased its stake in Masimo by 851.6% in the 4th quarter. EverSource Wealth Advisors LLC now owns 295 shares of the medical equipment provider’s stock valued at $35,000 after buying an additional 264 shares during the period. 85.96% of the stock is owned by institutional investors and hedge funds.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.